# Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report

**Authors:** Yang Guangxu, Li Yao, Xie Jing, Liu Hongsheng

PMC · DOI: 10.3389/fonc.2025.1616075 · Frontiers in Oncology · 2025-06-25

## TL;DR

A new ALK gene mutation was found in a rare thyroid tumor, offering new insights into its molecular features.

## Contribution

Identification of a novel ALK-R395H mutation in thyroid inflammatory myofibroblastic tumor.

## Key findings

- ALK-R395H mutation was detected in the extracellular domain of ALK in a thyroid IMT case.
- The tumor showed strong expression of thyroid epithelial markers and potential malignant features.
- The patient had no recurrence after 37 months post-surgery without adjuvant therapy.

## Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue neoplasm, exceptionally uncommon in the thyroid. Approximately 50%–70% of IMT cases exhibit ALK gene rearrangements or fusions, while ALK point mutations are rare. We report a novel ALK gene mutation, ALK-R395H, in a case of thyroid IMT and review the relevant literature.

A 43-year-old female patient presented with a thyroid mass discovered two months prior. Ultrasound revealed a solid hypoechoic mass in the middle of the left thyroid lobe. Histopathology showed characteristic spindle cell proliferation with plasma cell and lymphocyte infiltration. Immunohistochemistry demonstrated strong expression of Vimentin and ALK-1 in spindle cells, focal SMA expression, and strong positivity for Galectin-3, PAX-8, and TTF-1. Next-generation sequencing identified mutations in NTRK1, GNAS, RB1, and ALK, with a G1184A mutation in ALK exon 5, resulting in a missense mutation ALK(p.R395H) in the extracellular domain, the function of which remains to be elucidated. The pathological diagnosis was thyroid IMT; however, strong expression of thyroid epithelial markers and the ALK mutation suggested possible thyroid carcinoma components or malignant potential. The patient underwent left thyroid lobectomy with isthmus resection, received no adjuvant therapy, and showed no recurrence after 37 months of follow-up.

This case reports the discovery of the ALK-R395H mutation in thyroid IMT, providing new insights into its molecular characteristics.

## Linked entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238], NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914], GNAS (GNAS complex locus) [NCBI Gene 2778], RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925]
- **Proteins:** ACVRL1 (activin A receptor like type 1), PRELID1 (PRELI domain containing 1), SMN1 (survival of motor neuron 1, telomeric), LGALS3 (galectin 3), PAX8 (paired box 8), TTF1 (transcription termination factor 1)
- **Diseases:** inflammatory myofibroblastic tumor (MONDO:0015798), thyroid carcinoma (MONDO:0015075)

## Full-text entities

- **Genes:** NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, VIM (vimentin) [NCBI Gene 7431], LGALS3 (galectin 3) [NCBI Gene 3958] {aka CBP35, GAL3, GALBP, GALIG, L31, LGALS2}, SLPI (secretory leukocyte peptidase inhibitor) [NCBI Gene 6590] {aka ALK1, ALP, BLPI, HUSI, HUSI-1, HUSI-I}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}
- **Diseases:** inflammatory myofibroblastic tumor of the thyroid (MESH:D013964), IMT (MESH:D009369), thyroid mass (MESH:C536030)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G1184A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12237923/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12237923/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12237923/full.md

---
Source: https://tomesphere.com/paper/PMC12237923